Physician profile
Ruth E Peevey
NPI 1740576586
$6,719.79
in general payments reported to CMS, 2019-2025
37 companies · $1,142 in 2025
The $1,142 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,168 · 2022: $1,241 · 2023: $1,757 · 2024: $1,412 · 2025: $1,142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,311.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,310.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,439.55 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,022.83 | 2021-2025 | |
| Lilly USA, LLC | $821.96 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $468.57 | 2021-2025 | Freestyle Libre 3 |
| Pfizer INC. | $450.53 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $413.88 | 2022-2025 | Rexulti, Abilify Maintena |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $251.23 | 2021-2025 | Xifaxan |
| Janssen Pharmaceuticals, INC | $232.06 | 2021-2025 | Spravato |
| Amgen INC. | $212.45 | 2023-2025 | Evenity, Prolia, Repatha |
| Glaxosmithkline, LLC. | $114.87 | 2021-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Astellas Pharma US INC | $110.71 | 2022-2025 | Veozah |
| Biohaven Pharmaceutical Holding Company Ltd. | $109.66 | 2022 | |
| Exact Sciences Corporation | $105.92 | 2023-2024 | Cologuard Collection Kit |
| Lundbeck LLC | $96.62 | 2021-2025 | Rexulti |
| Dexcom, INC. | $86.61 | 2021-2025 | Dexcom G6 Transmitter |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ruth Peevey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.